A Phase III, randomized, open-label, multicenter, global study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC w

Condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sponsor: AstraZeneca

Phase:

A Phase III, randomized, open-label, multicenter, global study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations: AVANZAR